Teva Pharmaceutical Industries Limited (TEVA) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Limited (TEVA) Profile & Business Summary
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Key Information
| Ticker | TEVA |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.tevapharm.com |
Market Trend Overview for TEVA
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-08-10 (ET)
As of 2026-08-10, TEVA is in a strong upward move. Over the longer term, the trend remains bullish.
TEVA last closed at 36.14. The price is about 1.4 ATR above its recent average price (34.50), and the market is currently in a strong upward move. Price at 36.14 is holding above minor support near 33.78. If price continues higher, it may face minor resistance around 37.85. View Support & Resistance from Options
Short-term and long-term trends are aligned, and momentum remains healthy, supporting further upside.
Trend score: 95 out of 100. Overall alignment is strong. The market is currently in a strong and established uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 30.37. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-07-29, reflecting a technical shift toward positive directional alignment.
Recent price action shows orderly upward progression with no major deterioration in bar-level efficiency. Structural conditions remain broadly constructive.
Buying pressure built into the close, but price action was choppy and lacked clean follow-through.
The model sees a credible bullish edge, with 70.8% upside probability, strong signal alignment, and reward/risk that remains meaningfully favorable.
Up probability is 70.8%, with predictability at 66% and signal agreement at 100%. Reversal risk is 15%, while reward/risk stands at 0.51. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 13 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-08-10. The current price is 36.14, 6.50% above the estimated average cost of 33.94. An estimated 100.0% of recent positioning is below the current price, while 0.0% is above it. The peak-density price is 34.44. The largest concentrated cost region is 34.19 to 35.49 and contains 63.3% of the estimated distribution. The nearest region below the current price is 34.19 to 35.49.
Short Interest & Covering Risk for TEVA
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 23%)
Structure Analysis
TEVA Short positioning is starting to look crowded. Current days to cover is 6.5 trading days, meaning short positions would unwind more slowly than usual. Short covering could add extra momentum to price moves. No meaningful structural fragility is currently detected (Fragility Score 37/100, DTC percentile 99%) while price maintains a mild upward bias (20D return 7.3%) with short positioning continuing to expand and liquidity softening modestly (volume -20%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility. Short positioning is at extreme historical levels.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. In the latest reporting period, short interest continues to increase. Price action is compressing (range is tightening), which can make breaks more sensitive. Price is consolidating near highs with a weak upward bias; surface strength may mask a more fragile structure. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. High-level consolidation and compression suggest a fragile upside structure. As a result, similar news or market events could lead to price moves about 3× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-07-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.